Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
IPO Year:
Exchange: NASDAQ
Website: profoundmedical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/23/2024 | $16.50 | Buy | Lake Street |
| 7/16/2024 | $9.00 → $12.00 | Hold → Buy | Stifel |
| 11/28/2023 | $11.00 | Hold | Stifel |
| 8/4/2023 | $20.00 → $200.00 | Strong Buy → Outperform | Raymond James |
| 3/21/2023 | $5.50 → $10.00 | Buy → Hold | Jefferies |
| 3/7/2022 | $28.00 → $14.00 | Outperform | Cowen & Co. |
| 2/22/2022 | $28.00 → $23.00 | Strong Buy → Outperform | Raymond James |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Lake Street initiated coverage of Profound Medical with a rating of Buy and set a new price target of $16.50
Stifel upgraded Profound Medical from Hold to Buy and set a new price target of $12.00 from $9.00 previously
Stifel initiated coverage of Profound Medical with a rating of Hold and set a new price target of $11.00
Raymond James downgraded Profound Medical from Strong Buy to Outperform and set a new price target of $200.00 from $20.00 previously
Jefferies downgraded Profound Medical from Buy to Hold and set a new price target of $10.00 from $5.50 previously
Cowen & Co. reiterated coverage of Profound Medical with a rating of Outperform and set a new price target of $14.00 from $28.00 previously
Raymond James downgraded Profound Medical from Strong Buy to Outperform and set a new price target of $23.00 from $28.00 previously
Raymond James initiated coverage of Profound Medical with a rating of Strong-Buy and set a new price target of $34.00
Lake Street Capital reiterated coverage of Profound Medical with a rating of and set a new price target of $32.00 from $27.00 previously
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Profound Medical Corp. (0001628808) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Profound Medical Corp. (0001628808) (Issuer)
8-K - Profound Medical Corp. (0001628808) (Filer)
8-K - Profound Medical Corp. (0001628808) (Filer)
8-K - Profound Medical Corp. (0001628808) (Filer)
8-K - Profound Medical Corp. (0001628808) (Filer)
8-K - Profound Medical Corp. (0001628808) (Filer)
8-K - Profound Medical Corp. (0001628808) (Filer)
424B5 - Profound Medical Corp. (0001628808) (Filer)
8-K - Profound Medical Corp. (0001628808) (Filer)
EFFECT - Profound Medical Corp. (0001628808) (Filer)
8-K - Profound Medical Corp. (0001628808) (Filer)
Fastest customizable press release news feed in the world
TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today that PRO FAMILIA Specialist Hospital in Rzeszów, Poland has completed its 500th Sonalleve® Procedure. The MRI-guided therapy provides women with a non-surgical alternative for treating common gynecologic conditions—delivering targeted relief with no incisions, no blood loss during the procedure, no overnight hospital stay, and a faster recovery. "Sonalleve is giving more women access to a safer, gentler a
TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce its participation in the following investor events in February. Lake Street Life-Sciences Invitational: Profound is scheduled to participate in a series of one-on-one meetings February 4th-5th in Scottsdale, AZ.BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference: The Company is scheduled to participate in a series of one-on-one meetings February 10th-11th in Snowbir
Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World Report® for 2025-26 TORONTO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce the world-renowned Mount Sinai Hospital has successfully treated its first prostate cancer patient with the TULSA-PRO® system. The TULSA Procedure™ represents a major advancement in pr
TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that its TULSA-PRO® system installed base stood at 78 as of December 31, 2025 — higher than its previously announced goal of 75 installs by the end of 2025. Profound's TULSA-PRO qualified sales pipeline also grew to 97 new systems being classified within one of the "Verify, Negotiate and Contracting" stages at year-end. "As the installed base grows, we expect that it will lead to higher patient tr
TORONTO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced that The Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the Company's TULSA-PRO® system. The milestone marks the official launch of TULSA-PRO at one of the world's most influential centers for prostate cancer innovation and coincides with the opening of Johns Hopkins Medicine's new interventional MRI ("iMRI") suite — signaling the continued evolution of MRI fr
TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") is pleased to announce that it has completed its previously announced private placement of common shares to Canadian investors (the "Offering"). Pursuant to the Offering, the Company issued an aggregate of 921,428 common shares at a price of US$7.00 per common share, for aggregate gross proceeds of approximately US$6.45 million. The common shares sold pursuant to the Offering are subject to a hold period of four months plus one day from the closing date of the Offering under Canadian securities laws. The Company intends to use the net proceeds from the Offering for expa
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") is pleased to announce that it has increased the size of its private placement previously announced on December 19, 2025 (the "Offering") in order to accommodate participation by a long-term existing investor. The Company will now raise gross proceeds of up to US$6.45 million in the Offering, through the issuance of up to 921,428 common shares at a price of US$7.00 per common share. The common shares sold pursuant to the Offering will be subject to a hold period of four months plus one day from the closing date of the Offering. The closing of the Offering is expected to
TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") today announced the closing of its previously announced registered direct offering of 5,142,870 common shares at a purchase price of $7.00 per share, for gross proceeds of approximately $36 million before fees and expenses. The registered direct offering was structured as a straightforward equity investment with no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders. Gross proceeds to the Company from the registered direct offering were approximately $36 million, before deducting placement agent's fees and other offering expense
TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a registered direct offering and a planned subsequent private placement in Canada of up to 571,428 common shares at a purchase price of $7.00 per share for aggregate gross proceeds of up to $40 million. The registered direct offering was structured as a straightforward equity investment with no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders. This portion of the offering is expected to close on or about Monday, December 22, 2025, sub
TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that Pejman Ghanouni, MD, PhD, Associate Professor in the Department of Radiology, Division of Body MRI at Stanford University School of Medicine, has received the Cum Laude award for his presentation titled "CAPTAIN Randomized Controlled Trial of MRI-Guided Transurethral Ultrasound Ablation (TULSA) Versus Robotic Radical Prostatectomy" at the 2025 Radiological Society of North America ("RSNA") Annu
Live Leadership Updates
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the "Meeting"). A total of 20,587,011 common shares, representing 68.5% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 4, 2025 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders
– Mr. Tamberrino and Profound's CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final preparations for the permanent CPT® Category 1 codes for TULSA going into effect at the beginning of 2025 – TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the appointment of Tom Tamberrino as its new Chief Commercial Officer. Abbey Goodman, the Company's current CCO, will t
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the "Meeting"). A total of 15,336,388 common shares, representing 62.78% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 5, 2024 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the Comp
TORONTO, May 15, 2024 /CNW/ - Profound Medical Corp. (TSX:PRN) (NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the "Meeting"). A total of 15,336,388 common shares, representing 62.78% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 5, 2024 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the Company elected all
TORONTO, May 17, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual and Special Meeting of Shareholders that was held today (the "Meeting"). A total of 13,437,920 common shares, representing 63.64% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 6, 2023 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the
TORONTO, May 18, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual and Special Meeting of Shareholders that was held today (the "Meeting"). A total of 12,858,319 common shares, representing 61.880% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 8, 2022 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the sharehol
TORONTO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the appointment of accomplished global medical device industry veteran, Kenneth Knudson, as Chief Commercial Officer. Mr. Knudson's mandate will be leading Profound's worldwide sales, marketing and reimbursement activities. In an executive management career spanning more than 25 years, Mr. Knudson has achieved results ranging from accelerating growth for emerging start-ups to advancing success for Fortune 500 compa
TORONTO, May 19, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual Meeting of Shareholders that was held today (the "Meeting"). A total of 11,810,287 common shares, representing 58.044% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 9, 2021, were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the Company elected all seven nominees for th
HAMILTON, ON, April 29, 2021 /CNW/ - The Board of Directors for Insight Medbotics, a start-up founded by MDA and the Centre for Surgical Invention and Innovation (CSii), are pleased to announce the appointment of Paul Chipperton as the company's Chief Executive Officer & President. Mr. Chipperton will be responsible for ensuring the successful execution of existing projects, including the IGAR (Image Guided Automated Robot), the world's first Magnetic Resonance Imaging (MRI) guided breast cancer robot. Mr. Chipperton is a 25-year Medtech veteran, and has raised capital at al
TORONTO, March 03, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today the appointment of Cynthia Lavoie Ph.D., MBA, to its Board of Directors. A seasoned healthcare investment professional with 18 years of experience in venture capital, Dr. Lavoie’s expertise includes creating companies de novo and leading investments into businesses developing therapeutics, devices, and diagnostic tools. Dr. Lavoie is currently President and Managing Director of AllosteRx Capital Management (“AllosteRx”). She also
This live feed shows all institutional transactions in real time.
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
Live finance-specific insights
TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the third quarter ended September 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Revenue grew 87% year-over-year to a record $5.3 million in the third quarter of 2025.Gross margin increased 1,119 basis p
TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudited revenues for the third quarter of 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars. For the quarter ended September 30, 2025, Profound anticipates total revenues to be in the approximate range of $5.2 million to $5.3 million, representing revenue growth of between 84% and 87% over $2.8 million in the same three-month period a year ag
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the second quarter ended June 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Utilization of current TULSA-PRO® systems continues to grow, with "same store" procedure volumes up 10% sequentially from Q1-2
TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2025 financial results after market close on Thursday, August 14, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Second Quarter 2025 Results Conference Call Details: Date: Thursday, August 14, 2025 Time: 4:30 p.m. ET Live Call Registration: https://register-conf.media-server.com/register/BId8
TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the first quarter ended March 31, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Q1-2025 revenue growth of 82% over Q1-2024. Profound continued to see a wide variety of prostate disease patients treated by
TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. First Quarter 2025 Results Conference Call Details: Date: Thursday, May 8, 2025 Time: 4:30 p.m. ET Live Call Registration: https://register-conf.media-server.com/register/BI2ca675b1f05
TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the fourth quarter and full year ended December 31, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Q4-2024 revenue growth of 108% over Q4-2023.During the fourth quarter, Profound made two key executive changes to fur
TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Fourth Quarter and Full Year 2024 Results Conference Call Details: Date: Thursday, March 6, 2025 Time: 4:30 p.m. ET Live Call Registration: https://
TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Business Highlights Q3-2024 revenue growth of 64% over Q3-2023.Profound continued to see a wide variety of prostate dise
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Third Quarter 2024 Results Conference Call Details: Date: Thursday, November 7, 2024 Time: 4:30 p.m. ET Live Call Registration: https://register.vevent.com/register/BI0b43a811a8b6